New ConsumerGram: Lifesaving Drugs at Lower Costs

The Food and Drug Administration (FDA) began approving generic (unbranded) prescription drugs around 30 years ago, and generic drugs are now saving consumers more than one trillion dollars per decade in healthcare costs over their brand named counterparts.  Competition from generics has provided more options to doctors and better access to patients – at prices […]

ACI Asks FDA: Write Rules for Biosimilar Drug Market Entry

July 10, 2014 Ms. Margaret A. Hamburg Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Dear Commissioner Hamburg: On behalf of The American Consumer Institute (ACI), a nonprofit educational and research organization, we are writing to raise an issue of critical concern regarding the naming of biosimilar drugs.  We […]

ACI Expert to Speak on Biosimilars and Protecting R&D Dollars

Professor Joseph Fuhr Jr., ACI Senior Fellow and professor of Economics at Widener University, will be speaking on the challenges, lessons and opportunities in the marketing of biosimilars in the U.S. at the BioNJ Breakfast Salon in Bridgewater, NJ on June 2, 2011.

ACI Expert Prof. Fuhr Quoted in Genetic Engineering & Biotechnology News

Genetic Engineering & Biotechnology News quotes ACI Expert and Weidener University Economics Professor Joseph Fuhr, Jr at the following link.  The article notes the expected explosive growth of biosimilar sand follow-on biologics, but nonetheless expects competitors to proceed cautiously.

Dr. Joseph Fuhr Discusses Biosimilar Competition and Trends

Dr. Joseph P. Fuhr, Jr., ACI Senior Fellow and professor of Economics at Widener University, presented at CBI’s 6th Summit on Biosimilars and Follow-On Biologics.  His presentation “A Prospective Look at the Shape of Biosimilar and Innovator Companies in Five to Ten Years,” was presented on Wednesday, March 30, 2011.  His presentation included: An examination of paths […]

Professors Blackstone and Fuhr on the Benefits of Biosimilar Competition

  Benefits from Biosimilar Competition Erwin A. Blackstone and Joseph P. Fuhr, Jr. (For a printable version of this ConsumerGram with its footnotes, please click here biosimilar2-1)   The U.S. is now developing a process for expedited approval of biosimilars. Biopharmaceuticals are far more complex and costly to develop and produce than chemical drugs. Biosimilars […]

Biosimilars and Innovation: Article by Professors Blackstone and Fuhr

Professors Blackstone and Fuhr, both ACI experts, wrote an interesting article on the tradeoff of increased competition vs. increased innovation and the effects on drug prices.   The full citation is: Blackstone, Erwin A. and Fuhr, Joseph P., Jr., “Biosimilars and Innovation: An Analysis of the Possibility of Increased Competition in Biopharmaceuticals,” Future Medicinal Chemistry, vol 2, no. […]

Recent Presentations Made by ACI on Taxes, Solvency and Broadband Stimulus

Dr. Joseph P. Fuhr, “Why Biosimilars Will Have a Smaller Competitive Edge Than Generics,” presented at CBI’s Second Annual Summit on Biosimilars and Follow-on biologics, Baltimore, based on an article coauthored by Dr. Erwin A. Blackstone and published in the Journal of Health Care Finance, Winter 2008, pp. 84-95. Slides available. Steve Pociask, “Why Solvency Matters,” […]